Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Oct 8;32(10):549–552. doi: 10.1002/clc.20435

Statins as Anti‐Arrhythmics: A Systematic Review Part II: Effects on Risk of Ventricular Arrhythmias

Hussam Abuissa 1,, James H O'Keefe 1, Kevin A Bybee 1
PMCID: PMC6653011  PMID: 19816987

Abstract

Background

Recent studies have demonstrated that statins may possess anti‐arrhythmic properties in addition to their lipid‐lowering effects.

Methods

Studies which reported the association of statins with the incidence of ventricular arrhythmias were identified through a systematic review of the published literature.

Results

Statins have been associated with a significant reductions in ventricular arrhythmia in cardiomyopathy patients with an implantable cardioverter defibrillator, although randomized trials have not been completed.

Conclusions

Published data suggests that statins may possess anti‐arrhythmic properties that reduce the propensity for ventricular arrhythmias. Most of this data is observational; more randomized, placebo‐controlled trials are needed. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (145.2 KB).

References

  • 1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med Oct 3 1996; 335(14): 1001–1009. [DOI] [PubMed] [Google Scholar]
  • 2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet Jul 6 2002; 360(9326): 7–22. [DOI] [PubMed] [Google Scholar]
  • 3. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation Sep 1 1998; 98(9): 839–844. [DOI] [PubMed] [Google Scholar]
  • 4. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol Feb 1995; 15(2): 247–251. [DOI] [PubMed] [Google Scholar]
  • 5. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG‐coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation Mar 4 1997; 95(5): 1126–1131. [DOI] [PubMed] [Google Scholar]
  • 6. Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res Aug 1 2001; 51(2): 283–293. [DOI] [PubMed] [Google Scholar]
  • 7. Bybee KA, Kopecky SL, Williams BA, Murphy JG, Scott Wright R. Reduced creatine kinase release with statin use at the time of myocardial infarction. Int J Cardiol Sep 2004; 96(3): 461–466. [DOI] [PubMed] [Google Scholar]
  • 8. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail Dec 2005; 11(9): 684–690. [DOI] [PubMed] [Google Scholar]
  • 9. Welzig CM, Shin DG, Park HJ, Kim YJ, Saul JP, et al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasymp‐ athetic responsiveness. Circulation Dec 2 2003; 108(22): 2743–2746. [DOI] [PubMed] [Google Scholar]
  • 10. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G. Lipid lowering drugs and recurrences of life‐threatening ventricular arrhythmias in high‐risk patients. J Am Coll Cardiol Sep 2000; 36(3): 766–772. [DOI] [PubMed] [Google Scholar]
  • 11. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP. Are lipid‐lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol Jul 2 2003; 42(1): 81–87. [DOI] [PubMed] [Google Scholar]
  • 12. Chiu JH, Abdelhadi RH, Chung MK, Gurm HS, Marrouche NF, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implant‐ able cardioverter‐defibrillator. Am J Cardiol Feb 15 2005; 95(4): 490–491. [DOI] [PubMed] [Google Scholar]
  • 13. Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)‐II. J Am Coll Cardiol Feb 21 2006; 47(4): 769–773. [DOI] [PubMed] [Google Scholar]
  • 14. Goldberger JJ, Subacius H, Schaechter A, Howard A, Berger R, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol Sep 19 2006; 48(6): 1228–1233. [DOI] [PubMed] [Google Scholar]
  • 15. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med Nov 29 2007; 357(22): 2248–2261. [DOI] [PubMed] [Google Scholar]
  • 16. Dickinson MG, Ip JH, Olshansky B, Hellkamp AS, Anderson J, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD‐HeFT). Am Heart J Apr 2007; 153(4): 573–578. [DOI] [PubMed] [Google Scholar]
  • 17. Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation Feb 28 2006; 113(8): 1086–1092. [DOI] [PubMed] [Google Scholar]
  • 18. Rosolova H, Cech J, Simon J, Spinar J, Jandova R, et al. Short to long term mortality of patients hospitalised with heart failure in the Czech Republic–a report from the EuroHeart Failure Survey. Eur J Heart Fail Aug 2005; 7(5): 780–783. [DOI] [PubMed] [Google Scholar]
  • 19. Levantesi G, Scarano M, Marfisi R, Borrelli G, Rutjes AW, et al. Meta‐analysis of effect of statin treatment on risk of sudden death. Am J Cardiol Dec 1 2007; 100(11): 1644–1650. [DOI] [PubMed] [Google Scholar]
  • 20. Yamada T, Node K, Mine T, Morita T, Kioka H, et al. Long‐term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J Jun 2007; 153(6): 1055 e1051–1058. [DOI] [PubMed] [Google Scholar]
  • 21. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non‐ischemic heart failure. J Am Coll Cardiol Feb 18 2004; 43(4): 642–648. [DOI] [PubMed] [Google Scholar]
  • 22. Budaj A, Cybulski J, Cedro K, Karczmarewicz S, Maciejewicz J, et al. Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Randomized, placebo‐controlled substudy of ISIS‐4. Eur Heart J Oct 1996; 17(10): 1506–1510. [DOI] [PubMed] [Google Scholar]
  • 23. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet Aug 7 1999; 354(9177): 447–455. [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES